|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
189,490,000 |
Market
Cap: |
1.17(B) |
Last
Volume: |
2,941,111 |
Avg
Vol: |
4,440,946 |
52
Week Range: |
$4.13 - $7.98 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 16.9 |
Insider 6 Months : 16.9 |
Insider 3/6 Months : 32.4 |
|
Guru Rank Number : 455 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
Total People Bought |
10 |
10 |
10 |
10 |
Total Buy Transactions |
10 |
10 |
10 |
10 |
Total Shares Sold |
0 |
0 |
0 |
495,199 |
Total Sell Value |
$0 |
$0 |
$0 |
$5,999,241 |
Total People Sold |
0 |
0 |
0 |
9 |
Total Sell Transactions |
0 |
0 |
0 |
14 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baker Felix |
10% Owner |
|
2015-11-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,918 |
|
- |
|
Sanders Charles A |
Director |
|
2015-08-31 |
4 |
A |
$11.64 |
$8,742 |
D/D |
751 |
7,751 |
|
- |
|
Hutson Nancy J |
Director |
|
2015-08-31 |
4 |
A |
$11.64 |
$8,742 |
D/D |
751 |
16,642 |
|
- |
|
Cohen Fred E |
Director |
|
2015-08-31 |
4 |
A |
$11.64 |
$8,742 |
D/D |
751 |
103,845 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-07-20 |
4 |
AS |
$16.50 |
$57,750 |
D/D |
(3,500) |
142,644 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-07-15 |
4 |
D |
$15.67 |
$399,992 |
D/D |
(25,526) |
659,211 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-07-15 |
4 |
OE |
$11.81 |
$399,981 |
D/D |
33,868 |
684,737 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-22 |
4 |
AS |
$16.00 |
$60,000 |
D/D |
(3,750) |
146,144 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-22 |
4 |
OE |
$4.73 |
$17,738 |
D/D |
3,750 |
149,894 |
|
- |
|
Barnes Alane P |
VP, General Counsel & Corp Sec |
|
2015-06-19 |
4 |
AS |
$15.00 |
$45,000 |
D/D |
(3,000) |
68,876 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-06-19 |
4 |
AS |
$15.05 |
$1,059,354 |
D/D |
(70,389) |
95,123 |
|
- |
|
Sheridan William P |
Senior VP - CMO |
|
2015-06-19 |
4 |
OE |
$1.20 |
$84,467 |
D/D |
70,389 |
165,512 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-19 |
4 |
AS |
$15.00 |
$100,125 |
D/D |
(6,675) |
146,144 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-19 |
4 |
OE |
$3.78 |
$12,002 |
D/D |
3,175 |
149,319 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-06-19 |
4 |
S |
$15.02 |
$300,400 |
D/D |
(20,000) |
650,869 |
|
- |
|
Stonehouse Jon P |
President & CEO |
|
2015-06-19 |
4 |
OE |
$1.20 |
$24,000 |
D/D |
20,000 |
670,869 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-18 |
4 |
AS |
$13.50 |
$135,025 |
D/D |
(9,700) |
149,644 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-18 |
4 |
OE |
$3.78 |
$23,436 |
D/D |
6,200 |
155,844 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-05 |
4 |
AS |
$12.75 |
$76,500 |
D/D |
(6,000) |
153,144 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-06-01 |
4 |
AS |
$12.00 |
$36,000 |
D/D |
(3,000) |
159,144 |
|
- |
|
Cohen Fred E |
Director |
|
2015-05-29 |
4 |
A |
$11.21 |
$8,744 |
D/D |
780 |
103,094 |
|
- |
|
Staab Thomas R Ii |
Senior Vice President and CFO |
|
2015-05-18 |
4 |
AS |
$11.00 |
$33,000 |
D/D |
(3,000) |
162,144 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-19 |
4 |
S |
$10.16 |
$122,987 |
D/D |
(12,105) |
148,697 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-05 |
4 |
S |
$10.59 |
$396,066 |
D/D |
(37,400) |
160,802 |
|
- |
|
Babu Yarlagadda S |
Senior VP - Drug Discovery |
|
2015-03-04 |
4 |
S |
$10.50 |
$110,198 |
D/D |
(10,495) |
198,202 |
|
- |
|
753 Records found
|
|
Page 18 of 31 |
|
|